Viking Therapeutics to Showcase VK2735 Data at the 2026 European Congress on Obesity

Viking Therapeutics to Present at the European Congress on Obesity 2026

Viking Therapeutics, Inc., a biopharmaceutical firm focused on innovative therapies for metabolic and endocrine conditions, is set to present its research on VK2735 at the 33rd European Congress on Obesity (ECO) 2026, taking place in Istanbul from May 12 to 15. This event will mark a significant occasion for Viking as it highlights pivotal advancements in treatments for obesity through their dual agonist product, VK2735.

VK2735 is designed as a dual agonist targeting the glucagon-like peptide-1 (GLP-1) and the glucose-dependent insulinotropic polypeptide (GIP) receptors. It's currently evaluated in both oral and subcutaneous formulations intended for managing metabolic disorders, especially obesity. The upcoming poster presentations will shine a light on the data gathered from the 13-week Phase 2 VENTURE-Oral trial focused on VK2735, which assessed its efficacy and safety in terms of weight loss and tolerability.

Presentation Highlights

The two posters being showcased include:
1. Title: Treatment with Oral VK2735 Results in Significant Weight Loss - The Randomized, Placebo-Controlled, Dose-Finding VENTURE-Oral Study
Publication Number: PO4.260
Presented by: Karen Modesto, M.D., Vice President of Clinical Development
Display Date/Time: May 12-15, with networking session on May 14 from 18:00 - 19:15 Turkey Time
Location: Poster area at Level B5, Istanbul Congress Center

2. Title: VANQUISH-1 Phase 3 Trial With Enrollment of a Diverse Population to Test Efficacy of Subcutaneous VK2735 in Adults with Obesity or Overweight with Weight-Related Comorbidities
Publication Number: PO4.278
Presented by: Karen Modesto, M.D., Vice President of Clinical Development
Display Date/Time: May 12-15, with networking session on May 14 from 18:00 - 19:15 Turkey Time
Location: Poster area at Level B5, Istanbul Congress Center

These presentations are particularly important as they offer insights into VK2735's potential to address obesity—a condition affecting millions globally. The efficacy data presented may contribute to a better understanding of innovative treatment strategies possible through VK2735.

Insights on VK2735

The dual action of VK2735 aims to activate both GLP-1 and GIP receptors. Activation of the GLP-1 receptor is associated with a reduction in glucose levels, appetite suppression, and improved insulin sensitivity, key factors in managing diabetes and obesity. Prior research has indicated success in activating these receptors, like the notable results seen in semaglutide, a currently approved GLP-1 receptor agonist. Viking Therapeutics hopes that combining these mechanisms may yield enhanced clinical benefits for patients battling metabolic disorders.

Dr. Karen Modesto, who leads the clinical development, expressed optimism regarding the presentations. She aims to illustrate the robustness of the data from these trials, potentially paving the way for VK2735 to become a viable treatment option for patients requiring new obesity therapies.

Additionally, Viking is parked at a promising intersection of health sciences, showcasing multiple projects under development, including VK2809 for lipid and metabolic disorders, and VK0214 targeting rare diseases like X-ALD.

As Viking Therapeutics prepares for its participation at ECO 2026, the company is poised to take significant steps in the fight against obesity and improve the quality of life for those affected.

For more information on Viking Therapeutics and its ongoing research, please visit Viking Therapeutics' official website.

Note: This news piece contains forward-looking statements that may be influenced by various risks and uncertainties that impact the company’s development and clinical trial outcomes. Interested parties should keep abreast of Viking Therapeutics' reports and updates as they progress in their research endeavors.